{
  "ProtocolSection": {
    "IdentificationModule": {
      "NCTId": "NCT00698191",
      "OrgStudyIdInfo": {
        "OrgStudyId": "NSFC30772014"
      },
      "Organization": {
        "OrgFullName": "Nanjing Medical University",
        "OrgClass": "OTHER"
      },
      "BriefTitle": "Mesenchymal Stem Cells Transplantation for Refractory Systemic Lupus Erythematosus (SLE)",
      "OfficialTitle": "Phase I/IIa: Allogeneic Bone Marrow Derived Mesenchymal Stem Cells Transplantation For Refractory Systemic Lupus Erythematosus"
    },
    "StatusModule": {
      "StatusVerifiedDate": "June 2008",
      "OverallStatus": "Unknown status",
      "LastKnownStatus": "Recruiting",
      "ExpandedAccessInfo": {
        "HasExpandedAccess": "No"
      },
      "StartDateStruct": {
        "StartDate": "March 2007"
      },
      "PrimaryCompletionDateStruct": {
        "PrimaryCompletionDate": "December 2011",
        "PrimaryCompletionDateType": "Anticipated"
      },
      "CompletionDateStruct": {
        "CompletionDate": "December 2012",
        "CompletionDateType": "Anticipated"
      },
      "StudyFirstSubmitDate": "June 13, 2008",
      "StudyFirstSubmitQCDate": "June 16, 2008",
      "StudyFirstPostDateStruct": {
        "StudyFirstPostDate": "June 17, 2008",
        "StudyFirstPostDateType": "Estimate"
      },
      "LastUpdateSubmitDate": "June 16, 2008",
      "LastUpdatePostDateStruct": {
        "LastUpdatePostDate": "June 17, 2008",
        "LastUpdatePostDateType": "Estimate"
      }
    },
    "SponsorCollaboratorsModule": {
      "ResponsibleParty": {
        "ResponsiblePartyOldNameTitle": "Sun, Lingyun/ Prof.",
        "ResponsiblePartyOldOrganization": "Nanjing University Medical College Affiliated Drum Tower Hospital"
      },
      "LeadSponsor": {
        "LeadSponsorName": "Nanjing Medical University",
        "LeadSponsorClass": "OTHER"
      },
      "CollaboratorList": {
        "Collaborator": [
          {
            "CollaboratorName": "National Natural Science Foundation of China",
            "CollaboratorClass": "OTHER_GOV"
          }
        ]
      }
    },
    "OversightModule": {
      "OversightHasDMC": "Yes"
    },
    "DescriptionModule": {
      "BriefSummary": "This study will explore a new approach to treat patients with a medical condition known as systemic lupus erythematosus (SLE) who have been resistant to previous treatments using a new population of cells with capability to restore a normal immune system that will no longer attack the body.\n\nThe stated hypothesis is that the SLE condition is caused by an abnormal immune system that can be restored by replenishing the body with a new population of progenitor cells.",
      "DetailedDescription": "The purpose of this study is to evaluate the safety and efficacy of allogeneic bone marrow derived mesenchymal stem cell (AlloMSC) transplantation in patients with refractory SLE. Patients with Lupus nephritis and refractory to corticosteroid or cyclophosphamide trials will be enrolled in this trial. The treatment intervention includes a 24 hour pretreatment with cyclophosphamide followed by AlloMSC transplantation. Patients will be admitted to the in-patient service for the 3-5 days for the transplant treatment and will be followed up in the outpatient clinic. All baseline lupus serology, renal function panels will be obtained at pre-treatment admission. Post-transplantation follow-up visits will be at monthly intervals for lupus serology and renal function tests, and every 3 months for analysis of T regulatory population. The transplanted patients will be evaluated by an integrated team of rheumatologists, hematologists and bone marrow transplant specialists every month for the entire duration of the trial (2 years) and every 6-12 months thereafter."
    },
    "ConditionsModule": {
      "ConditionList": {
        "Condition": [
          "Refractory Systemic Lupus Erythematosus"
        ]
      },
      "KeywordList": {
        "Keyword": [
          "Lupus Erythematosus,Systemic",
          "Lupus Nephritis",
          "Mesenchymal Stem Cells",
          "Transplantation"
        ]
      }
    },
    "DesignModule": {
      "StudyType": "Interventional",
      "PhaseList": {
        "Phase": [
          "Phase 1",
          "Phase 2"
        ]
      },
      "DesignInfo": {
        "DesignAllocation": "Non-Randomized",
        "DesignInterventionModel": "Single Group Assignment",
        "DesignPrimaryPurpose": "Treatment",
        "DesignMaskingInfo": {
          "DesignMasking": "None (Open Label)"
        }
      },
      "EnrollmentInfo": {
        "EnrollmentCount": "20",
        "EnrollmentType": "Anticipated"
      }
    },
    "ArmsInterventionsModule": {
      "ArmGroupList": {
        "ArmGroup": [
          {
            "ArmGroupLabel": "1",
            "ArmGroupType": "Experimental",
            "ArmGroupInterventionList": {
              "ArmGroupInterventionName": [
                "Biological: Allogeneic MSC (AlloMSC)"
              ]
            }
          }
        ]
      },
      "InterventionList": {
        "Intervention": [
          {
            "InterventionType": "Biological",
            "InterventionName": "Allogeneic MSC (AlloMSC)",
            "InterventionDescription": "Intervention:\n\nCyclophosphamide will be administered intravenously at at total dose of 0.8-1.8g 24 hours before transplantation.\n\nAllogeneic bone marrow derived mesenchymal stem cells (matched family donors)will be infused intravenously at 106 cells/kg body weight",
            "InterventionArmGroupLabelList": {
              "InterventionArmGroupLabel": [
                "1"
              ]
            }
          }
        ]
      }
    },
    "OutcomesModule": {
      "PrimaryOutcomeList": {
        "PrimaryOutcome": [
          {
            "PrimaryOutcomeMeasure": "Systemic Lupus Erythematosus Disease Activity Index (SLEDAI)",
            "PrimaryOutcomeTimeFrame": "Monthly"
          },
          {
            "PrimaryOutcomeMeasure": "Lupus serology (ANA, dsDNA, C3, C4)",
            "PrimaryOutcomeTimeFrame": "Monthly"
          },
          {
            "PrimaryOutcomeMeasure": "Renal function (GFR, BUN, urinalysis)",
            "PrimaryOutcomeTimeFrame": "Monthly"
          }
        ]
      },
      "SecondaryOutcomeList": {
        "SecondaryOutcome": [
          {
            "SecondaryOutcomeMeasure": "Percentage of systemic T regulatory population",
            "SecondaryOutcomeTimeFrame": "Every 3 months"
          }
        ]
      }
    },
    "EligibilityModule": {
      "EligibilityCriteria": "Inclusion Criteria:\n\nAll patients fulfilled the American College of Rheumatology (ACR) criteria of SLE, man or woman aged from 15 to 70 years old, SLEDAI≥8;\nLupus nephritis with 24h urine protein≥1g;\n\nRefractory disease as determined by failure of the following regimens:\n\nTrial of corticosteroids (oral prednisone more than 20 mg/day);\nTrial of cyclophosphamide 0.4 ~ 0.6 / m2 every two weeks for six months, or other immunosuppressive drugs, such as MMF 2 g / day, for three months;\nPatients must sign an informed consent indicating that they are aware of the investigational nature of the study in keeping with the policy of the hospital;\nWilling to use contraception throughout the study and for 12 mos following treatment.\n\nExclusion Criteria:\n\nAbnormal liver function (ALT higher than 3 times the normal value);\nEnd-stage renal failure;\nSevere heart and pulmonary failure, or other important organs damage;\nUndercontrolled infections\nPregnant or breast feeding women, male or female who intended to recent pregnancy.",
      "HealthyVolunteers": "No",
      "Gender": "All",
      "MinimumAge": "15 Years",
      "MaximumAge": "70 Years",
      "StdAgeList": {
        "StdAge": [
          "Child",
          "Adult",
          "Older Adult"
        ]
      }
    },
    "ContactsLocationsModule": {
      "CentralContactList": {
        "CentralContact": [
          {
            "CentralContactName": "Sun Lingyun, MD",
            "CentralContactRole": "Contact",
            "CentralContactPhone": "+86 25 83105219",
            "CentralContactEMail": "lingyunsun2001@yahoo.com.cn"
          }
        ]
      },
      "OverallOfficialList": {
        "OverallOfficial": [
          {
            "OverallOfficialName": "Lingyun Sun, M.D.",
            "OverallOfficialAffiliation": "Nanjing University Medical College Affiliated Drum Tower Hospital",
            "OverallOfficialRole": "Study Director"
          }
        ]
      },
      "LocationList": {
        "Location": [
          {
            "LocationFacility": "Department of Rheumatology and Immunology, Nanjing University Medical College Affiliated Drum Tower Hospital",
            "LocationStatus": "Recruiting",
            "LocationCity": "Nanjing",
            "LocationState": "Jiangsu",
            "LocationZip": "210008",
            "LocationCountry": "China",
            "LocationContactList": {
              "LocationContact": [
                {
                  "LocationContactName": "Sun Lingyun, MD",
                  "LocationContactRole": "Contact",
                  "LocationContactPhone": "+86 25 83105219",
                  "LocationContactEMail": "lingyunsun2001@yahoo.com.cn"
                }
              ]
            }
          }
        ]
      }
    },
    "ReferencesModule": {
      "ReferenceList": {
        "Reference": [
          {
            "ReferencePMID": "18389442",
            "ReferenceType": "background",
            "ReferenceCitation": "Jiang B, Sun L, Hao S, Li X, Xu Y, Hou Y. Estrogen modulates bone marrow-derived DCs in SLE murine model-(NZB x NZW) F1 female mice. Immunol Invest. 2008;37(3):227-43. doi: 10.1080/08820130801973328."
          },
          {
            "ReferencePMID": "18061155",
            "ReferenceType": "background",
            "ReferenceCitation": "Jiang B, Sun L, Hao S, Li X, Hou Y. Estrogen distinctively modulates spleen DC from (NZB x NZW) F1 female mice in various disease development stages. Cell Immunol. 2007 Aug;248(2):95-102. Epub 2007 Dec 3."
          },
          {
            "ReferencePMID": "17402368",
            "ReferenceType": "background",
            "ReferenceCitation": "Sun LY, Zhang HY, Feng XB, Hou YY, Lu LW, Fan LM. Abnormality of bone marrow-derived mesenchymal stem cells in patients with systemic lupus erythematosus. Lupus. 2007;16(2):121-8."
          },
          {
            "ReferencePMID": "30428931",
            "ReferenceType": "derived",
            "ReferenceCitation": "Liang J, Zhang H, Kong W, Deng W, Wang D, Feng X, Zhao C, Hua B, Wang H, Sun L. Safety analysis in patients with autoimmune disease receiving allogeneic mesenchymal stem cells infusion: a long-term retrospective study. Stem Cell Res Ther. 2018 Nov 14;9(1):312. doi: 10.1186/s13287-018-1053-4."
          }
        ]
      }
    }
  },
  "DerivedSection": {
    "MiscInfoModule": {
      "VersionHolder": "January 20, 2022"
    },
    "ConditionBrowseModule": {
      "ConditionMeshList": {
        "ConditionMesh": [
          {
            "ConditionMeshId": "D000008180",
            "ConditionMeshTerm": "Lupus Erythematosus, Systemic"
          }
        ]
      },
      "ConditionAncestorList": {
        "ConditionAncestor": [
          {
            "ConditionAncestorId": "D000003240",
            "ConditionAncestorTerm": "Connective Tissue Diseases"
          },
          {
            "ConditionAncestorId": "D000001327",
            "ConditionAncestorTerm": "Autoimmune Diseases"
          },
          {
            "ConditionAncestorId": "D000007154",
            "ConditionAncestorTerm": "Immune System Diseases"
          }
        ]
      },
      "ConditionBrowseLeafList": {
        "ConditionBrowseLeaf": [
          {
            "ConditionBrowseLeafId": "M11490",
            "ConditionBrowseLeafName": "Nephritis",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M10330",
            "ConditionBrowseLeafName": "Lupus Nephritis",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M10329",
            "ConditionBrowseLeafName": "Lupus Erythematosus, Systemic",
            "ConditionBrowseLeafAsFound": "Systemic Lupus Erythematosus",
            "ConditionBrowseLeafRelevance": "high"
          },
          {
            "ConditionBrowseLeafId": "M5616",
            "ConditionBrowseLeafName": "Connective Tissue Diseases",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M3781",
            "ConditionBrowseLeafName": "Autoimmune Diseases",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M9352",
            "ConditionBrowseLeafName": "Immune System Diseases",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "T3523",
            "ConditionBrowseLeafName": "Lupus Nephritis",
            "ConditionBrowseLeafRelevance": "low"
          }
        ]
      },
      "ConditionBrowseBranchList": {
        "ConditionBrowseBranch": [
          {
            "ConditionBrowseBranchAbbrev": "BXS",
            "ConditionBrowseBranchName": "Urinary Tract, Sexual Organs, and Pregnancy Conditions"
          },
          {
            "ConditionBrowseBranchAbbrev": "All",
            "ConditionBrowseBranchName": "All Conditions"
          },
          {
            "ConditionBrowseBranchAbbrev": "BC17",
            "ConditionBrowseBranchName": "Skin and Connective Tissue Diseases"
          },
          {
            "ConditionBrowseBranchAbbrev": "BC20",
            "ConditionBrowseBranchName": "Immune System Diseases"
          },
          {
            "ConditionBrowseBranchAbbrev": "Rare",
            "ConditionBrowseBranchName": "Rare Diseases"
          }
        ]
      }
    },
    "InterventionBrowseModule": {
      "InterventionBrowseLeafList": {
        "InterventionBrowseLeaf": [
          {
            "InterventionBrowseLeafId": "M5879",
            "InterventionBrowseLeafName": "Cyclophosphamide",
            "InterventionBrowseLeafRelevance": "low"
          }
        ]
      },
      "InterventionBrowseBranchList": {
        "InterventionBrowseBranch": [
          {
            "InterventionBrowseBranchAbbrev": "ANeo",
            "InterventionBrowseBranchName": "Antineoplastic Agents"
          },
          {
            "InterventionBrowseBranchAbbrev": "ARhu",
            "InterventionBrowseBranchName": "Antirheumatic Agents"
          },
          {
            "InterventionBrowseBranchAbbrev": "All",
            "InterventionBrowseBranchName": "All Drugs and Chemicals"
          }
        ]
      }
    }
  }
}